Visceral leishmaniasis (VL) is a vector-borne disease caused by Leishmania donovani complex. Post-kala-azar dermal leishmaniasis (PKDL) is a rash that can occur following treatment for VL due to L. donovani species. We describe an unusual case of PKDL occurring during treatment for Leishmania infantum VL in a patient with human immunodeficiency virus-co infection.
Nelson M, Dockrell DH and Edwards S on behalf of the BHIVA Guidelines Subcommittee. British HIV association and British infection association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals. HIV Med 2011; 12(Suppl. 2): 1--140.
AkuffoHCostaCvan GriensvenJ, et al.
New insights into leishmaniasis in the immunosuppressed.PLoS Negl Trop Dis2018;
12: e0006375.
4.
PaglianoPEspositoS.Visceral leishmaniosis in immunocompromised host: an update and literature review. J Chemother2017;
29: 261–266.
5.
Alves de Lima Henn G, Novaes Ramos Junior A, Keby Baima Colares J, et al. Is visceral leishmaniasis the same in HIV-coinfected adults? Braz J Infect Dis 2018; 22: 92--98.
6.
GoncLOBadaroRGoisLL, et al.
Leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients: a literature review. J Int Assoc Provid AIDS Care2014;
14: 1–6.
7.
BoschRJRodrigoABSanchezP, et al.
Presence of leishmania organisms in specific and non-specific skin lesions in HIV-infected individuals with visceral leishmaniasis. Int J Dermatol2002;
41: 670–675.
8.
CelesiaBMCacopardoBMassiminoD, et al.
Atypical presentation of PKDL due to Leishmania infantum in an HIV-infected patient with relapsing visceral leishmaniasis. Case Rep Infect Dis2014;
2014: 370286.
9.
LindosoJALMoreiraCHVCelesteBJ, et al.
Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report. Rev Soc Bras Med Trop2018;
51: 105–107.
10.
CarnaúbaDKonishiCTPetriV, et al.
Atypical disseminated leishmaniasis similar to post-kala-azar dermal leishmaniasis in a Brazilian AIDS patient infected with Leishmania (Leishmania) infantum chagasi: a case report. Int J Infect Dis2009;
13: 504–507.
11.
ZijlstraEE.PKDL and other dermal lesions in HIV co-infected patients with leishmaniasis: review of clinical presentation in relation to immune responses. PLoS Negl Trop Dis2014;
8: e3258.
12.
World Health Organization Regional Office for Europe. Manual on case management and surveillance of the leishmaniases in the WHO European Region. Denmark: World Health Organization Regional Office for Europe,2017.
13.
AbongomeraCDiroEde Lima PereiraA, et al.
The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: a retrospective cohort study.PLoS Negl Trop Dis2018;
12: e0006527.
14.
Monge-MailloBNormanFFCruzI, et al.
Visceral leishmaniasis and HIV coinfection in the Mediterranean region. PLoS Negl Trop Dis2014;
8: e3021.
